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Abstract: BACKGROUND: The effect of anesthetic drugs on cancer outcomes remains unclear. This
trial aimed to assess postoperative circulating tumor cell counts-an independent prognostic factor for
breast cancer-to determine how anesthesia may indirectly affect prognosis. It was hypothesized that
patients receiving sevoflurane would have higher postoperative tumor cell counts. METHODS: The
parallel, randomized controlled trial was conducted in two centers in Switzerland. Patients aged 18 to
85 yr without metastases and scheduled for primary breast cancer surgery were eligible. The patients
were randomly assigned to either sevoflurane or propofol anesthesia. The patients and outcome assessors
were blinded. The primary outcome was circulating tumor cell counts over time, assessed at three
time points postoperatively (0, 48, and 72 h) by the CellSearch assay. Secondary outcomes included
maximal circulating tumor cells value, positivity (cutoff: at least 1 and at least 5 tumor cells/7.5 ml
blood), and the association between natural killer cell activity and tumor cell counts. This trial was
registered with ClinicalTrials.gov (NCT02005770). RESULTS: Between March 2014 and April 2018,
210 participants were enrolled, assigned to sevoflurane (n = 107) or propofol (n = 103) anesthesia, and
eventually included in the analysis. Anesthesia type did not affect circulating tumor cell counts over time
(median circulating tumor cell count [interquartile range]; for propofol: 1 [0 to 4] at 0 h, 1 [0 to 2] at 48
h, and 0 [0 to 1] at 72 h; and for sevoflurane: 1 [0 to 4] at 0 h, 0 [0 to 2] at 48 h, and 1 [0 to 2] at 72 h;
rate ratio, 1.27 [95% CI, 0.95 to 1.71]; P = 0.103) or positivity. In one secondary analysis, administrating
sevoflurane led to a significant increase in maximal tumor cell counts postoperatively. There was no
association between natural killer cell activity and circulating tumor cell counts. CONCLUSIONS: In
this randomized controlled trial investigating the effect of anesthesia on an independent prognostic factor
for breast cancer, there was no difference between sevoflurane and propofol with respect to circulating
tumor cell counts over time.
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The effect of anesthetic drugs on cancer outcomes remains unclear. We aimed to assess 
postoperative circulating tumor cells counts - an independent prognostic factor for breast 
cancer - to understand how anesthesia may indirectly affect prognosis. We hypothesized 
patients receiving sevoflurane would have higher postoperative tumor cells counts. 
Methods 
Parallel, randomized controlled trial conducted in two centers in Switzerland. Patients aged 
18-85 years without metastases and scheduled for primary breast cancer surgery were 
eligible. Patients were randomly assigned to either sevoflurane or propofol anesthesia. 
Patients and outcome assessors were blinded. The primary outcome was circulating tumor 
cells counts over time, assessed at three time points postoperatively (0h, 48h, and 72h) by 
the CellSearch® assay. Secondary outcomes included maximal circulating tumor cells value, 
positivity (cut-off: ≥1 and ≥5 tumor cells/7.5ml blood), and the association between natural 
killer cell activity and tumor cells counts. This trial was registered with ClinicalTrials.gov 
(NCT02005770). 
Results 
Between March 2014 and April 2018, 210 participants were enrolled, assigned to 
sevoflurane (n=107) or propofol (n=103) anesthesia, and eventually included in the analysis. 
Anesthesia type did not affect circulating tumor cells counts over time (median CTC count 
[IQR] propofol: 1 [0-4] at 0h, 1 [0-2] at 48h, and 0 [0-1] at 72 h; sevoflurane: 1 [0-4] at 0h, 0 
[0-2] at 48h and 1 [0-2] at 72h; rate ratio 1.27 [95%CI 0.95 – 1.71]; p=0.103) or positivity. In 




tumor cells counts postoperatively. There was no association between natural killer cell 
activity and circulating tumor cells counts. 
Conclusions 
In this randomized controlled trial investigating the effect of anesthesia on an independent 
prognostic factor for breast cancer, there was no difference between sevoflurane or 























Breast cancer represents a major health issue: with more than 2 million new cases 
worldwide,1 it is the most frequently diagnosed tumor and the leading cause of cancer 
deaths in women.2 Despite primary treatment, between 6% of patients with localized 
tumors and 22% with nodal extension will face recurrence at 5 years.3  
Most patients diagnosed with breast cancer undergo surgical treatment. There have been 
increasing concerns, however, that the perioperative period would promote tumor 
spreading, either directly (i.e. through tumor manipulation), or indirectly, since systemic 
inflammation may affect immune responses against tumor cells.4 Evidence also suggests 
that anesthesia itself may contribute to distant spread: anesthetic drugs seem to interfere 
directly with tumor cell biology and to decrease natural killer cells cytotoxic activity, which 
plays a critical role in tumor cell destruction and tumor growth.5,6 
Although these effects have been well documented in pre-clinical studies, their relevance in 
the clinical setting is still matter of debate: intravenous anesthesia has been suggested to 
result in better survival rates compared to inhalational anesthesia, but evidence was mostly 
driven by retrospective analyses, which are prone to important methodological limitations.7-
14 Conflicting findings also emerged from a few randomized controlled trials suggesting no 
effect on survival, but sample sizes were small, follow-up duration short, and multiple 
interventions were evaluated without an adequate control group.15-17  
Large, well-designed randomized controlled trial are thus needed to clarify the effect of 
anesthetic drugs on cancer prognosis, but long follow-up periods often undermine the 
feasibility of such studies.    
To overcome this issue, the use of biological markers as surrogates for prognosis may 




the peripheral blood has been identified as a particularly promising indicator.19 
Hematogenous dissemination seems to occur long before clinical or radiological signs of 
metastases develop,20 which places circulating tumor cells at an ideal location in the causal 
pathway leading to distant disease.21 There is also increasing evidence that circulating 
tumor cells are independently associated with a higher risk of disease recurrence and with 
reduced survival, both in non-metastatic and metastatic breast cancer.22,23 In this respect, 
circulating tumor cells monitoring may represent a promising approach to better 
understand the effect of anesthesia on tumor behavior during the perioperative period.  
Therefore, we conducted a randomized controlled trial to evaluate the effect of intravenous 
(i.e. propofol) versus inhalational (i.e. sevoflurane) anesthesia on postoperative circulating 
tumor cells counts in primary breast cancer patients. A superiority design was used to test 
the hypothesis that postoperative circulating tumor cells counts would be higher in patients 
receiving sevoflurane. The association between immune cell responses (i.e. natural killer cell 
cytotoxic activity) and circulating tumor cells counts was assessed in an exploratory in vitro 














We used the CONSORT recommendations for the reporting of randomized trials.24 This trial 
was approved by the local ethical committee (Zurich, Switzerland – Registration number: 
PB_2016-01791) and was registered with ClinicalTrials.gov (NCT02005770 - 
https://clinicaltrials.gov/ct2/show/NCT02005770 - Principal investigator: Beatrice Beck-
Schimmer, registration date: December 9, 2013). The study protocol is available on 
ClinicalTrials.gov. 
Trial Design and Participants 
This was a parallel-group, randomized, controlled trial conducted at a university hospital 
(University Hospital of Zurich) and a private clinic (Hirslanden Group, Zurich) in Switzerland. 
Patients were considered eligible if they were aged 18 to 85 years, diagnosed with primary 
pre-invasive and invasive breast cancer without distant metastases (stage 0-III) and 
scheduled for surgery with or without axillary node dissection. Patients were excluded if 
they met one of the following criteria: pre-operative chemotherapy, possible immune 
impairment (i.e. auto-immune disease, HIV, other active cancer, American Society of 
Anesthesiologists (ASA) physical status IV-V), immunosuppressive or chronic opioids 
therapy, secondary surgery (e.g. for recurrence, reconstruction) or surgery performed under 
general anesthesia with concomitant regional anesthesia (i.e. epidural catheter, 
paravertebral blockade, wound infiltration with local anesthetics). Those with a known or 
suspected hypersensitivity or allergy to anesthetics were considered ineligible. Patients 
were approached on the day prior to surgery by research staff, who evaluated eligibility, 
obtained written informed consent, and enrolled the participants.  




Randomization was performed by research staff using a secure Internet-based system 
(www.randomiser.at) that stratified patients according to their ASA status and ensured 
concealment of random allocation. Patients were randomly assigned in a 1:1 ratio to either 
intravenous anesthesia (propofol group) or inhalational anesthesia (sevoflurane group). 
Patients remained blinded of their assignment group (standardized induction in both 
groups), as was the study personnel involved in circulating tumor cells measurements (i.e. 
outcome assessors did not have access to patient charts).  
Procedures 
Anesthesia induction was standardized in both groups using fentanyl (2-3 mcg/kg), 
thiopental (4-6 mg/kg) and rocuronium (0.6 mg/kg). Patients requiring a rapid sequence 
induction received rocuronium 0.9 mg/kg instead of 0.6 mg/kg. Further administration of 
fentanyl during surgery followed a standardized protocol (i.e. 2 mcg/kg, total amount: 5-10 
mcg/kg). In the propofol group, anesthesia was maintained using a target-controlled 
infusion (TCI) device providing an intravenous propofol dose adjusted to keep bispectral 
(BIS) index values between 40 and 60; in the sevoflurane group, sevoflurane was provided 
to keep BIS index values between 40 and 60. Postoperative nausea and vomiting prophylaxis 
and perioperative analgesia followed standardized protocols that were applied until hospital 
discharge.  
Outcome 
The primary outcome was the number of circulating tumor cells assessed postoperatively by 
the CellSearch® assay (Menarini Silicon Biosystems Inc, Huntingdon Valley, PA, USA). Based 
on immunomagnetic separation, this detection technique uses a magnetic field to isolate 
ferrofluid-labelled tumor cells of epithelial origin, such as breast cancer cells.25 This 




displayed by circulating tumor cells in breast cancer patients 
(i.e."EpCAM+/CK+/DAPI+/CD45-" signature – EpCAM: epithelial cell adhesion molecule; CK: 
cytokeratin; DAPI: 4ʹ,6-diamidino-2-phenylindole). After staining of the isolated cells, 
circulating tumor cells identification was confirmed by two independent, specifically trained 
laboratory technicians that were masked to treatment assignment. Identification of 
circulating tumor cells followed a predefined set of criteria (i.e. morphological features, 
compatible staining pattern).  
Peripheral blood was collected at four different time points, i.e. before the induction of 
anesthesia (baseline), after surgery but prior to extubation (0h), at day-2 (48h) and day-3 
(72h) postoperatively. The last measurement (72h) was initially planned on day-4, but was 
rescheduled to day-3 in January 2016 to avoid data loss due to early hospital discharge. This 
was the only change made to the original trial design. 
Secondary outcomes were defined as: the maximal circulating tumor cells count value at 
any time point after surgery (0h, 48h and 72h); circulating tumor cells counts as a binary 
outcome (using 2 different cut-off values, i.e. ≥1 and≥5 circulating tumor cells/7.5ml blood); 
and the association between natural killer cell activity and circulating tumor cells counts 
(see also section "additional analyses"). Initially, only a cut-off value of ≥5 circulating tumor 
cells/7.5ml blood was considered. We added the ≥1 threshold at the time of analysis, since 
evidence suggested that values as low as 1 circulating tumor cell/7.5ml blood were 
associated with poorer prognosis in primary breast cancer patients.22 No other changes 
were made to primary/secondary outcomes definitions over the study period.   
Statistical analyses 
Sample size calculation was performed using a method accounting for repeated 




inhalational anesthesia on circulating tumor cells counts was nonexistent, we adopted a 
conservative approach and assumed that the expected effect size (Cohen’s d) between 
groups would be small (0.3). Thus, assuming a within-subject correlation of circulating 
tumor cells counts over time of 0.4 and a dropout rate of 10%, we estimated that a total of 
232 patients would be required (209 patients without dropout) to detect a difference 
between groups corresponding to an effect size of 0.3, with a power of 80%, at a 
significance level of 5% (two-sided). Because the dropout rate was particularly low, the trial 
ended after enrolling 217 patients. 
All analyses were based on intention-to-treat. Continuous data were expressed as means 
and standard deviations or as medians and interquartile ranges if distributions were 
skewed. The primary analysis used a mixed Poisson model with random intercept per 
patient to account for repeated measurements over time and thus correlated observations 
within-subjects. We opted for this approach, since the Poisson model is appropriate for 
count data (primary outcome of CTC counts). The results of the Poisson models are 
presented as rate ratios, denoting the comparison of circulating tumor cells counts between 
the two groups. To avoid assuming a linear development of circulating tumor cells over 
time, time was alternatively included as a factor variable in our model. We also explored the 
effect of anesthetics on the maximal circulating tumor cells count value at any time point 
after surgery in additional Poisson models (0h, 48h and 72h).  
Since circulating tumor cells detection is usually reported as a binary outcome (i.e. positive 
versus negative endpoint using a cut-off value of ≥1 or ≥5 circulating tumor cells/7.5ml 
blood), circulating tumor cells count data were dichotomized and further assessed using a 




Finally, models were adjusted to account for tumor-related and perioperative factors 
presumed to affect circulating tumor cells counts (i.e. tumor size, tumor type, overall 
opioids consumption – all preplanned). 
All statistical analyses were conducted in R, version 3.6.1. Two-sided tests were performed 
and a level of significance of 0.05 was used. 
Additional analyses 
Because of the interplay between natural killer cell cytotoxic activity and tumor growth, we 
also assessed natural killer cell activity (i.e. apoptosis rate induced in tumor cells) in a 
preplanned, exploratory, in vitro study nested within this trial. Natural killer cell-induced 
apoptosis was evaluated in a subgroup of patients randomly selected from the study 
dataset. For each patient, natural killer cell activity was assessed at a single, pre-defined 
time point, i.e. when circulating tumor cells counts reached their maximal value. The 
association between natural killer cell-induced apoptosis rate and circulating tumor cells 
count was then assessed using linear regression analysis.  
Natural killer cell-induced apoptosis rate and necrosis rate were determined in vitro by 
measuring target cell killing of the K562 tumor cell line (human chronic myelogenous 
leukemia, ATCC, CCL-243).27,28 Patients blood samples were collected in EDTA-coated vials. 
Buffy coats (Blutspende Zürich, Schlieren, Switzerland) were used as controls. Peripheral 
blood mononuclear cells (PBMC) of both patient samples and buffy coats were isolated by 
Ficoll-Hypaque density gradient centrifugation and stored in liquid nitrogen. For 
determination of natural killer cell activity, PBMC were thawed and co-incubated with K562 
for 24 h at 37°C/5% CO2 in 10% human serum/RPMI. An effector (natural killer cells) to 
target cell (K562 cells) ratio of 1:1 was used. All cells were then washed in phosphate-




the following panel: CD3-APC (lymphocyte staining, Biolegend, London, UK), dilution of 
1:100; CD 56-PE (natural killer cells staining, Biolegend, London, UK), dilution 1:100; CD16-
FITC (FcgRIIIA staining, which is essential for cellular cytotoxicity, expressed on the surface 
of a subset of monocytes, Biolegend, London, UK), dilution 1:200. After a washing step in 
Annexin-V binding buffer, cells were simultaneously stained with Annexin-PerCPCy5.5 for 
staining of apoptotic cells (Biolegend, London, UK) at a dilution of 1:20, and Zombie-NIR for 
staining of necrotic cells (Biolegend, London, UK) at a dilution of 1:500.  
Zombie-NIR-stained K562 boiled for 5 min at 80°C or Annexin-V-stained apoptotic K562, 
treated for 24h with 10 mM benzamide, were used as positive controls for cytotoxicity. 
Unstained K562, unstained patient PBMC and unstained PBMC from buffy coats served as 
negative controls. Cell analysis was performed using the spectral analyzer SP6800 (Sony 

















Between March 10, 2014 and April 10, 2018, 586 patients were assessed for eligibility 
(figure 1). Of 217 enrolled participants, seven patients withdrew consent after 
randomization. We eventually included 210 patients in the intention-to-treat analysis 
(sevoflurane group: n=107, propofol group: n=103).  
Baseline characteristics are presented in table 1. Demographic and clinical data were 
balanced between treatment groups. Most participants were middle aged, modestly morbid 
patients with an early-stage tumor. Baseline circulating tumor cells counts and positivity 
(using a cut-off value of ≥1 and ≥5 circulating tumor cells/7.5ml blood) were similar in both 
allocation groups. Table 2 depicts the intra- and postoperative characteristics, which were 
well-balanced between groups. 
The evolution of circulating tumor cells counts over time is illustrated in Figure 2, table 3, 
and Supplemental Digital Content Figure 1 (which depicts predicted tumor cell counts using 
the estimates from the Poisson model, including a linear time variable and baseline 
circulating tumor cell counts). Administrating sevoflurane versus propofol did not affect the 
primary outcome of circulating tumor cells counts over time (rate ratio 1.27 [95%CI 0.95 - 
1.71]; p = 0.103). This was the case, regardless of whether time was considered as a linear 
or a factor variable, or if an interaction term between time and anesthesia was introduced. 
However, when we explored the effect of anesthetics on the maximal circulating tumor cells 
value at any time point after surgery, administrating inhalational anesthesia (i.e. 
sevoflurane) led to a significant increase in maximal circulating tumor cells counts 
postoperatively (sevoflurane versus propofol: rate ratio 1.36 [95%CI 1.18 - 1.56]; p < 0.0001, 
i.e. the maximum number of circulating tumor cells increased by a factor of 1.36 (or 36 %) 




When circulating tumor cells were analyzed as a binary outcome over time, the type of 
anesthesia did not have any effect on circulating tumor cells positivity, regardless of the cut-
off value considered (cut-off value ≥1 circulating tumor cells/7.5ml blood: sevoflurane 
versus propofol, odds ratio 1.21 [95%CI 0.84 - 1.74]; p = 0.309; cut-off value ≥5 circulating 
tumor cells/7.5ml blood: sevoflurane versus propofol, odds ratio 1.59 [95%CI 0.86 - 3.01]; p 
= 0.139). Similar results were obtained when time was considered as a factor variable, and 
there was no evidence for an interaction between treatment and time. 
We performed predefined analyses to explore whether tumor-related and perioperative 
factors modified the effect of anesthetics on circulating tumor cells counts. Models adjusted 
for tumor type (DCIS, luminal A, luminal B, Triple negative, HER2 positive, other) and tumor 
size (Tis, T1, T2, T3, T4) did not reveal any relevant effect modification on circulating tumor 
cells counts over time or positivity (regardless of the cut-off value considered). Similarly, 
adjusting for opioid consumption did not yield any effect modification. In the exploratory 
models, however, the effect of inhalational anesthesia on maximal postoperative circulating 
tumor cells values remained robust (sevoflurane versus propofol, rate ratio 1.26 [95%CI 1.09 
- 1.47], p = 0.002, adjustment for tumor type, size and opioid consumption).  
Exploratory in vitro analyses were conducted in a subgroup of 60 patients randomly selected 
from the study dataset (30 in the sevoflurane group, 30 in the propofol group). Similar 
natural killer cell-induced apoptosis rates were found in both treatment groups (mean 
apoptosis rate, sevoflurane group: 34.7%; propofol group: 35.7%). Overall, necrosis rate of 
K562 tumor cells was below 1%. Linear regression yielded no evidence for an association 
between apoptosis rates and maximal circulating tumor cells counts (regression coefficient -




assignment, or whether an interaction term between anesthesia type and natural killer cell 



























In this randomized controlled trial including 210 participants undergoing surgery for primary 
breast cancer, the type of anesthesia did not seem to affect circulating tumor cells counts 
over time or circulating tumor cells positivity. In one secondary analysis, there was a 36% 
increase in the maximal number of postoperative circulating tumor cells in patients 
receiving inhalational anesthesia. Additional in vitro analyses in a random selection of 60 
patients did not reveal any evidence for an association between natural killer cell-induced 
apoptosis rates and maximal circulating tumor cells counts.  
This trial investigated the effect of anesthesia on perioperative circulating tumor cells 
counts, an independent prognostic factor for breast cancer. In contrast to previously 
published randomized trials,15-17 our study was larger, had an adequate control group, and 
the issue of long follow-up periods was mitigated by using a prognostic factor.  
In our trial, circulating tumor cells counts at baseline were higher than those reported in 
previous studies. Several reasons may account for this discrepancy: first, all of our patients 
underwent sentinel lymph node localization 18 to 24h before baseline circulating tumor 
cells assessment and we cannot formally exclude that an injection in the vicinity of the 
tumor would not lead to any circulating tumor cells release. Second, approximately 30% of 
our patients had wire-guided localization of the tumor, which implies direct manipulation of 
the tumor short before circulating tumor cells assessment.  
Since the identification of circulating tumor cells with the CellSearch® assay may imply some 
degree of subjectivity (i.e. images of potential tumor cells candidates are displayed to 
trained laboratory technicians and assessed following pre-defined criteria), we verified all 
samples with ³5 tumor cells/7.5ml blood using the automated software ACCEPT 




analysis).30 Overall, the comparison showed a good correlation (Supplemental Digital 
Content Figure 3, illustrating the correlation between these 2 methods). Compared to the 
ACCEPT software, there was an overestimation of circulating tumor cells counts by 1.66 
units with human assessment (Supplemental Digital Content Figure 4, illustrating the 
agreement between these 2 methods). However, in this validation analysis, only samples 
with high tumor cells counts were considered. This may bias the results towards an 
overestimation of the difference in means. In other words, if all samples, i.e. including those 
with 0 to 4 tumor cells/7.5ml blood had also been included, the difference in means of 1.66 
units would have likely been smaller. Secondly, the overestimation of 1.66 units was non-
differential, i.e. applied to both groups, regardless of treatment assignment. 
Apart from one secondary analysis, our findings contrast with numerous previously 
published studies suggesting better outcomes with the use of intravenous anesthesia. The 
potential reasons for this disparity are two-fold. Firstly, clinical studies reporting on cancer 
outcomes were based on retrospective data analyses,7-14 which are prone to bias and 
confounding. Secondly, evidence of a protective effect associated to propofol was partly 
driven by in vitro studies,31-35 which may not reflect the delicate interplay between immune 
and tumor cells observed in vivo. Our findings, however, are consistent with a recently 
published, large, randomized controlled trial addressing the effect of regional versus general 
anesthesia on breast cancer recurrence.36 Although this trial was not specifically designed to 
compare inhalational with intravenous anesthesia, most patients allocated to general 
anesthesia received sevoflurane, whilst those allocated to regional anesthesia received 
propofol. In line with our study, this trial failed to show any difference in cancer outcomes.  
Our results, however, need to be interpreted with caution. Firstly, we assumed circulating 




anesthesia on the risk of tumor recurrence, but we did not perform a long-term outcome 
analysis to confirm this assumption. Although many oncological markers seem to be ideally 
placed in the causal pathway leading to distant disease, several other factors will eventually 
be needed to result in metastatic spread and uncertainty regarding the ability of these 
prognostic factors to predict "hard endpoints" must be acknowledged.37 A second concern is 
that the exact meaning of circulating tumor cells changes in the perioperative period 
remains unclear. In studies investigating the predictive validity of circulating tumor cells 
changes in primary and metastatic breast cancer, patients converting from "positive" to 
"negative" status were found to have longer progression-free survival and overall survival 
than those with a persisting "positive" status.23,38-42 However, circulating tumor cells 
detection was performed over many weeks or months and there is no firm evidence that 
these findings also apply to the immediate and rather short perioperative period. Other 
limitations are inherent to the CellSearch assay itself. Whilst the pattern 
"EpCAM+/CK+/DAPI+/CD45-" is a widely accepted molecular circulating tumor cells 
signature, other combinations may also occur: it has been argued, for instance, that 7.8% to 
10.3% of breast cancers might lack EpCAM expression.43,44 Further skepticism has been 
partly related to the fact that for a given tumor, a variety of circulating tumor cells 
phenotypes seems to exist.45 Thus, in some patients included in our study, the ability to 
detect circulating tumor cells might have been hampered by the technique used. Finally, the 
in vitro analysis was performed in a sample of 60 patients only, thereby limiting our ability 
to fully assess the association between natural killer cell-induced apoptosis rates and 
circulating tumor cells counts. The risk of other sources of bias (such as selection, 




In this randomized controlled trial, we investigated the effect of anesthesia on an 
independent prognostic factor in primary breast cancer patients. There was no difference in 
circulating tumor cells counts over time or circulating tumor cells positivity between 
patients receiving sevoflurane or propofol. One secondary analysis suggested a favorable 
effect of propofol on maximal postoperative circulating tumor cells values. Trials collecting 
long-term outcomes (NCT02786329, NCT03034096, NCT01975064, and NCT02660411) will 
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Fig. 1. Flow diagram 
Fig. 2. Evolution of circulating tumor cells counts over time.  
Fig. 3. Scatter plot of natural killer cell activity and maximal circulating tumor cells counts, 
by treatment. 
 
Fig. 1. Flow diagram
586 patients assessed for eligibility
369 not eligible
306 not meeting inclusion criteria
63 declined to participate 
217 enrolled and randomly assigned 
107 assigned to intravenous anesthesia (propofol) 
103 included in intention-to-treat analysis 
4 did not receive 
intervention (reason: 
consent withdrawal)
103 received propofol 
110 assigned to inhalational anesthesia (sevoflurane)
107 included in intention-to-treat analysis 
107 received sevoflurane 
3 did not receive 
intervention (reason: 
consent withdrawal)















































































































































Fig. 3. Scatter plot of natural killer cell activity and maximal circulating tumor 





















































































Table 1. Baseline characteristics    
 Sevoflurane (n=107) Propofol (n=103)  
Age, years 59 (13) 59 (12) 
Body mass index, kilogram/square meter 26.7 (6.1) 26.2 (5.6) 
ASA class   
    I 29 (27.1) 25 (24.3) 
    II 73 (68.2) 73 (70.9) 
    III 5 (4.7) 5 (4.8) 
Tumor size   
    Carcinoma in situ  9 (8.4) 5 (4.9) 
    T1, < 2cm 55 (51.4) 55 (53.4)  
    T2, 2-5 cm 38 (35.5) 33 (32.0)  
    T3, > 5cm 3 (2.8) 7 (6.9)  
    T4, any size, growing into the chest wall or skin 1 (0.9) 2 (1.9)  
    Not reported 1 (0.9) 1 (1.0) 
Pathological nodal status   
    N0, node-negative  65 (60.7) 62 (60.2) 
    N1, 1-3 lymph nodes 29 (27.1) 22 (21.4) 
    N2, 4-9 lymph nodes 4 (3.7) 6 (5.8) 
    N3, >10 lymph nodes or infra-/supraclavicular 1 (0.9) 2 (1.9) 
    Not reported 8 (7.5) 11 (10.7) 
Receptors   
    Estrogen receptor - /Progesterone receptor - 11 (10.3) 12 (11.7)  
    Estrogen receptor +/Progesterone receptor - 9 (8.4) 7 (6.8)  
    Estrogen receptor -/Progesterone receptor + 0 (0) 0 (0) 
    Estrogen receptor +/Progesterone receptor + 85 (79.4) 76 (73.8)  
    Human epidermal growth factor 2 receptor +  
(immunohistochemistry score 3+)    
7 (6.5) 14 (13.6) 
Data are mean (SD) or n (%), unless otherwise specified. ASA: American Society of 
Anesthesiologists.  
Table 1. Baseline characteristics (continued)   
 Sevoflurane (n=107) Propofol (n=103)  
Tumor type*   
    Ductal carcinoma in situ 8 (7.5) 4 (3.9)  
    Luminal A 58 (54.2) 58 (56.3)  
    Luminal B 19 (17.8) 12 (11.7)  
    Triple negative 5 (4.7) 6 (5.8)  
    Human epidermal growth factor 2 receptor   
status positive (fluorescence in  
    situ hybridization) 
9 (8.4) 16 (15.5)  
    Other 2 (1.9) 3 (2.9)  
    Not reported 6 (5.6) 4 (3.9) 
Surgery type 
    Lumpectomy with lymph node resection 76 (71.0) 70 (68.0) 
    Lumpectomy without lymph node resection 6 (5.6) 5 (4.8) 
    Quadrantectomy with lymph node resection 5 (4.7) 3 (2.9) 
    Quadrantectomy without lymph node resection 0 (0.0) 1 (1.0) 
    Modified radical mastectomy 3 (2.8) 6 (5.8) 
    Radical mastectomy 13 (12.2) 14 (13.6) 
    Other 4 (3.7) 4 (3.9) 
Circulating tumor cells   
    Number, median [interquartile range] 1 [0 - 3] 1 [0 - 3] 
    Circulating tumor cells positivity, cut-off value:  
    ≥1 cell/7.5ml blood 
73 (69.5) 68 (68.7)  
    Circulating tumor cells positivity, cut-off value:  
    ≥5 cell/7.5ml blood 
18 (17.1) 15 (15.2)  
Data are mean (SD) or n (%), unless otherwise specified. *Based on guidelines from the European 
Group on Tumor Markers.  
 
Table 2. Intra- and postoperative characteristics   
 Sevoflurane (n=107) Propofol (n=103)  
Duration of anesthesia, min 163 (78) 167 (50) 
BIS value,  median [IQR] 43 [40 - 48] 36 [30 - 40] 
Core temperature, degrees Celsius 36.2 (0.5) 36.2 (0.4) 
Fentanyl, mg, median [IQR] 0.4 [0.4 - 0.5] 0.5 [0.4 - 0.6] 
Morphine PACU intravenous, mg, median [IQR] 0.0 [0.0 - 4.0] 0.0 [0.0 - 2.5] 
NSAID administration   
    Intraoperative 13 (12.2) 9 (8.7)  
    Postoperative 95 (88.8) 92 (89.3)  
Intraoperative radiotherapy  70 (65.4) 71 (68.9)  
Data are mean (SD) or n (%), unless otherwise specified. BIS: bispectral index; NSAID: non-steroidal 
antiinflammatory drugs; PACU: postanesthesia care unit. 
 
Table 3. Perioperative circulating tumor cells counts  
Time point Allocation group 
Number of 
patients 
Min Median IQR Max 
Baseline 
Sevoflurane 105 0 1 [0 - 3] 39 
Propofol 99 0 1 [0 - 3] 24 
0 hour 
Sevoflurane 107 0 1 [0 - 4] 26 
Propofol 100 0 1 [0 - 4] 12 
48 hours 
Sevoflurane 100 0 0 [0 - 2] 41 
Propofol 94 0 1 [0 - 2] 17 
72 hours 
Sevoflurane 81 0 1 [0 - 2] 12 
Propofol 79 0 0 [0 - 1] 12 
IQR: interquartile range. 
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Estimates from the Poisson model including a linear time variable and baseline circulating 
tumor cell counts were used to predict the mean response for each of the two treatment 
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Samples with ≥5 CTC/7.5ml 
blood (n=96)
Samples assessed with 
ACCEPT software (n=83)
Not found in image database (n=3)
Poor image quality (n=2)
ACCEPT assessment failed (n=8)
Supplemental Digital Content – May 2020  3 
 
 
Figure 4. Bland-Altman plot of original versus ACCEPT measurements 
 
 
 
 
 
 
 
 
 
